3,4-dihydro-5-methyl-1(2h)-isoquinolinone has been researched along with topotecan in 1 studies
Studies (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Trials (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Recent Studies (post-2010) (3,4-dihydro-5-methyl-1(2h)-isoquinolinone) | Studies (topotecan) | Trials (topotecan) | Recent Studies (post-2010) (topotecan) |
---|---|---|---|---|---|
16 | 0 | 2 | 2,392 | 626 | 792 |
Protein | Taxonomy | 3,4-dihydro-5-methyl-1(2h)-isoquinolinone (IC50) | topotecan (IC50) |
---|---|---|---|
Cytochrome P450 3A4 | Homo sapiens (human) | 1.5211 | |
DNA topoisomerase 1 | Homo sapiens (human) | 0.8525 | |
DNA topoisomerase 2-alpha | Homo sapiens (human) | 0.605 | |
DNA topoisomerase 2-beta | Homo sapiens (human) | 0.605 | |
Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.06 | |
Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 8.6 | |
Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.3 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.17 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Almassy, RJ; Boritzki, TJ; Calabrese, CR; Calvert, AH; Curtin, NJ; Ekkers, A; Golding, BT; Griffin, RJ; Hostomsky, Z; Kumpf, RA; Kyle, S; Li, J; Maegley, KA; Newell, DR; Thomas, HD; Tikhe, JG; Wang, LZ; Webber, SE; Yu, XH; Zhang, C | 1 |
1 other study(ies) available for 3,4-dihydro-5-methyl-1(2h)-isoquinolinone and topotecan
Article | Year |
---|---|
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2004 |